{
    "nct_id": "NCT05239468",
    "official_title": "A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination With Obeticholic Acid in Subjects With Primary Biliary Cholangitis",
    "inclusion_criteria": "* A definite or probable diagnosis of PBC\n* Qualifying ALP and/or bilirubin liver biochemistry values\n* Taking ursodeoxycholic acid (UDCA) for at least 12 months or no UDCA for 3 months before Day 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History or presence of other concomitant liver diseases\n* Presence of clinical complications of PBC\n* History or presence of decompensating events\n* Current or history of gallbladder disease\n* If female, known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating\n* Treatment with commercially available OCA or participation in a previous study involving OCA, or other farnesoid X receptor (FXR) agonists, or peroxisome proliferator activated receptor (PPAR)-agonists within 3 months before Screening\n* Unable to tolerate BZF or other fibrates, treatment with commercially available fibrates, or participation in a previous study involving fibrate within 3 months before Screening.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": ""
}